Remove Bioinformatics Remove Genotype Remove Life Science Remove Research
article thumbnail

LabCorp Backs Resolution Bioscience’s Liquid Biopsy Test for NSCLC

XTalks

The leading global life science company is set to introduce Resolution Bio’s ctDx Lung assay , a non-invasive liquid biopsy test for patients with non-small cell lung cancer (NSCLC). LabCorp (NYSE:LH) may help lead the way with its backing of Resolution Bioscience’s new diagnostic blood test for lung cancer.

Gene 105